

15th International Symposium on Ocular
Pharmacology and Therapeutics

ISOPT *Clinical.* Retina

November 7-9, 2019 | Valencia, Spain

PROGRAM

Secretariat:

Target Conferences Ltd.

65 Derech Menachem Begin

Tel Aviv 6713818, Israel

Tel: +972 3 5175150, Fax: +972 3 5175155

email: target@target-conferences.com



TABLE OF CONTENTS

	Page
Welcome	4
Committees	5
Invited Speakers.....	6
General Information.....	8
Scientific Program	
Thursday, November 7, 2019	11
Friday, November 8, 2019	21
Saturday, November 9, 2019	26
E-posters	34
Company Sponsored Session.....	38
Acknowledgements	39

Dear colleagues,

It is our great pleasure welcoming you to the **15th ISOPT Clinical, The Retina Chapter** in Valencia, Spain. This year's meeting will focus on the medical treatment of retinal diseases.

Extensive research & development efforts are invested in major retinal diseases: dry and wet AMD, RVO, diabetic retinopathy, macular and retinal edema, retinitis pigmentosa and other forms of inherited retinal degenerative diseases. Furthermore, retinal drug delivery research efforts focus on effective ways to deliver lead drugs to the retina while reducing repeated frequent intraocular injections.

ISOPT *Clinical*, Retina Chapter offers a comprehensive review of current status and near future of therapeutics in those fields of unmet medical need. A team of clinical investigators, clinicians, academy-based researchers, and industry leads are assembled here in Valencia to discuss those issues with interested audience.

The vision of ISOPT *Clinical* had evolved since 1995 centering on:

- Increasing knowledge and awareness of drug utilization in ophthalmology
- Reflecting innovations and their application in daily practice
- Bridging the present to the future

This is reflected in ISOPT *Clinical* mission:

- Discussion of treatment algorithms in major ophthalmic indications
- Implement data from clinical studies for daily practice
- Facilitate innovation – connecting innovators with clinicians
- Encourage meetings of young innovators with the pharma industry

ISOPT *Clinical* offers a relevant and updated scientific program in a relaxed atmosphere leading to direct interactions of its delegates.

We welcome you to Valencia,

Ron Neumann, MD

Sara Krupsky, MD

ISOPT *Clinical*, Chairs

COMMITTEES

Conference Chairs:

Sara Krupsky, Israel

Ron Neumann, Israel

Retina Chair:

Patricia Udaondo, Spain

Special Program Advisor:

Baruch D. Kuppermann, USA

Session Chairs & Moderators:

Albert Augustin, Germany

Paolo Lanzetta, Italy

Francine Behar-Cohen, France

Anat Loewenstein, Israel

Karina Berg, Norway

Tunde Peto, UK

Francesco Boscia, Italy

Jose María Ruiz Moreno, Spain

Usha Chakravarthy, UK

Manuel Saenz de Viteri, Spain

Arup Das, USA

Leopold Schmetterer, Singapore

Marc de Smet, Switzerland

Rufino Silva, Portugal

Margaret DeAngelis, USA

Diane Tang Liu, USA

Jose García Arumí, Spain

Stela Vujosevic, Italy

Neena Haider, USA

Javier Zarranz, Spain

Uday Kompella, USA

INVITED SPEAKERS

Alfredo Adan, Spain

Luis Arias Barquet, Spain

Albert Augustin, Germany

William Ayliffe, UK

Dimitri Azar, USA

Francesco Bandello, Italy

Francine Behar-Cohen, France

Karim Ben Mbarek, France

Karina Berg, Norway

Karine Bigot, France

Francesco Boscia, Italy

Julia Busik, USA

Enrique Cervera, Spain

Subrata Chakarabarti, Canada

Usha Chakravarthy, UK

Choi-Mun Chan, Singapore

Tat-Keong Chan, Singapore

Itay Chowers, Israel

Arup Das, USA

Marc de Smet, Switzerland

Margaret DeAngelis, USA

Ibraheem El Ghrably, Abu-Dhabi

Edward Feener, USA

Ignacio Flores-Moreno, Spain

Mathilde Gallice, France

Jose García Arumí, Spain

Alfredo Garcia-Layana, Spain

Martina Giannaccini, Italy

David Guyer, USA

Neena Haider, USA

Rocio Herrero-Varnell, Spain

Ashwath Jayagopal, Switzerland

Uday Kompella, USA

Renu Kowluru, USA

Barruch D. Kupperman, USA

Paolo Lanzetta, Italy

Tamar Levi Vineberg, Israel

Anat Loewenstein, Israel

Christina Martinez, UK

Susanne Mohr, USA

Jordi Mones, Spain

Angel Montero Carcaboso, Spain

Javier Montero Hernandez, Spain

Maria Cristina Parravano, Italy

Bikash Pattnaik, USA

John Penn, USA

Tunde Peto, UK

Jorge Ruiz Medrano, Spain

INVITED SPEAKERS (CONT.)

Jose Maria Ruiz Moreno, Spain

Manuel Saenz de Viteri, Spain

Leopold Schmetterer, Singapore

Rufino Silva, Portugal

Debasish Sinha, USA

Diane Tang-Liu, USA

Patricia Udaondo, Spain

J. Pablo Velazquez-Martin, USA

Stela Vujosevic, Italy

Javier Zarranz, Spain

GENERAL INFORMATION

VENUE

Santiago Grisolia Auditorium
Science Museum Príncipe Felipe (El Museu de les Ciències
Príncipe Felipe)
City of Arts and Sciences (Ciudad de las Artes y de las Ciencias)
Av Profesor López Piñero, 7
46013 Valencia, Spain

LANGUAGE

The Symposium will be conducted in English.

REGISTRATION / HOSPITALITY / INFORMATION

A registration and hospitality desk will operate in the foyer of the Santiago Grisolia Auditorium at the City of Arts and Sciences, during session hours.

SESSION HALL

All sessions will take place in the Santiago Grisolia Auditorium.

NAME BADGE

Your name badge is included in the material which you received upon registration. Please wear your badge to all sessions.

SPEAKER PRESENTATIONS

Participants who will be giving a talk should bring their PowerPoint presentation on a USB memory stick. Please meet with the technician in the hall at least two hours before your session, or the day before, to load your presentation onto the Symposium computer.

SYMPOSIUM APP

The full program as well as abstracts of free papers and posters can be viewed on the Symposium app. Login details for the app were sent to you prior to the Symposium. If you do not have the information available, please ask at the registration desk.

GENERAL INFORMATION (CONT.)

E-POSTERS

The Symposium will feature electronic posters, which will be presented on a plasma screens in the foyer area. Presenters are requested to refer to the mobile app, or to pages 34-37 of the program to find the e-poster number assigned to them.

SOCIAL EVENTS

SCIENCE MUSEUM and GET-TOGETHER RECEPTION

Thursday, November 7, 18:00

There will be a special opening of the Science Museum in honor of the ISOPT *Clinical* participants, immediately following sessions. After the Museum visit we will reconvene in the foyer of the Grisolia Auditorium to mingle over snacks and drinks.

All registered participants are invited.

CONFERENCE ORGANIZERS

Target Conferences Ltd.

Tel: +972 3 5175150

Fax: +972 3 5175155

E-mail: ISOPT@target-conferences.com

SCIENTIFIC PROGRAM

Thursday, November 7, 2019

08:30 - 09:30 **UVEITIS**
Chair: **Ron Neumann**, Israel

LONG TERM SYSTEMIC EFFECTS OF IMMUNOSUPPRESSIVE DRUGS

08:30 Steroids
Francine Behar-Cohen, France

08:35 TNF inhibitors
Alfredo Adan, Spain

08:40 Methotrexate
William Ayliffe, UK

08:45 Mycophenolate mofetil
Marc de Smet, Switzerland

08:50 Discussion
Session Speakers
Moderator: **Ron Neumann**, Israel

Total burden on health of systemic therapy
Topical/systemic drugs decision making
Allowing development of cataract vs. long term effects of systemic therapy
The art of discontinuing systemic therapy
Vaccinations and epidemics in modern times and the immunosuppressed patient

09:30 *Coffee break*

Thursday, November 7, 2019 (CONT.)

10:00 -11:00 **KEYNOTE LECTURE & FREE PAPERS**
Chair: **Baruch Kuppermann**, USA

KEYNOTE LECTURE:

10:00 Lessons learned in ophthalmic biotech as a CEO, venture capitalist and clinician
David Guyer, USA

FREE PAPERS

10:15 The 3-year RETRO-IDEAL study - comparing visual acuity outcomes in patients with poor and good baseline vision
Albert Augustin, Germany

10:20 Real-world evidence in DME with aflibercept: 24 months of follow-up
Patricia Udaondo, Spain

10:25 Correlation of OCT biomarkers with aqueous humor biopsy results in DME
Paula Martínez López Corell, Spain

10:30 Diabetic macular edema (DME) treatment, responders and nonresponders
Enesa Begovic, Bosnia and Herzegovina

10:35 Importance of inflammation in choroidal thinning in diabetes
Martin Puzo Bayod, Spain

10:40 Transplantation of human iPS cells-derived RPE cell suspension into the subretinal space of a swine model of geographic atrophy
Lucia Lee Ferraro, Spain

Thursday, November 7, 2019 (CONT.)

- 10:00 -11:00 **FREE PAPERS (CONT.)**
Chair: **Baruch Kuppermann**, USA
- 10:45 Biodegradable intraocular implant loaded with adenosine A3
receptor agonist affords protection against retinal ischemic injury
Ana Raquel Santiago, Portugal
- 10:50 Pharmacokinetics and tissue distribution of atropine after single
and repeated topical instillation in rabbits
Xin Zhao, China
- 10:55 Q&A
-

- 11:00 - 12:00 **ENDOPHTHALMITIS**
Chair: **Anat Loewenstein**, Israel
- 11:00 Intraocular drug-related complications of endophthalmitis
prophylaxis
Tat Keong Chan, Singapore
- 11:10 Diagnostic vitrectomy for suspect endophthalmitis
Anat Loewenstein, Israel
- 11:20 Panel: antibiotics for intraocular infections?
Moderator: **Anat Loewenstein**, Israel
- Discussants:
Patricia Udaondo, Spain
Alfredo Adan, Spain
Alfredo Garcia-Layana, Spain
- How should antibiotics be used? For how long?
Vitrectomy - when?

Thursday, November 7, 2019 (CONT.)

- 11:00 - 12:00 **ENDOPHTHALMITIS (CONT.)**
Chair: **Anat Loewenstein**, Israel
- 11:40 CMV retinitis in iatrogenic immunosuppression: role for intravitreal ganciclovir
Ana Maria Cunha, Portugal
- 11:45 Human herpesvirus type 6 - the unlikely agent
Ana Maria Cunha, Portugal
- 11:50 Ozurdex implant migration into the anterior chamber: risk factors and management
Siddarth Nardeosingh, UK
- 11:55 Bilateral simultaneous neovascularization associated to choriorretinal lesions in a patient with previous non-filiated chronic anterior uveitis: which is the diagnosis?
Raquel Burggraaf Sánchez De Las Matas, Spain

12:00 *Lunch*

-
- 12:30 - 13:30 **FREE PAPERS**
Chair: **Baruch Kuppermann**, USA
-

- 12:30 Primary results from phase 2 Study of risuteganib in intermediate dry age-related macular degeneration
Baruch Kuppermann, USA
- 12:40 One year outcomes of 4-week extension of treatment interval in a treat-and-extend regimen with aflibercept for exudative age-related macular degeneration
Teresa Diago, Spain

Thursday, November 7, 2019 (CONT.)

- 12:30 - 13:30 **FREE PAPERS (CONT.)**
Chair: **Baruch Kuppermann**, USA
- 12:45 Ranibizumab vs aflibercept for neovascular AMD in an innovative setting for intravitreal injection: bari policlinico real-world experience
Maria Oliva Grassi, Italy
- 12:50 Time to dry analysis of brolocizumab versus aflibercept in patients with neovascular age-related macular degeneration: 96-week data from the HAWK and HARRIER trials
Javier Montero Hernandez, Spain
- 12:55 Simultaneous neutralization of angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) with faricimab: a review of the phase 2 clinical trials in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
Jordi Mones, Spain
- 13:00 Management of chronic central serous chorioretinopathy with mineralcorticoide and nanosecond laser
Marina Aguilar González, Spain
- 13:05 Improving diagnosis in chronic serous corioretinopathy
Miriam Rahhal Ortuño, Spain
- 13:10 Trimethoprim / Sulfamethoxazole as a first-line treatment in ocular toxoplasmosis
Alex Samir Fernández Santodomingo, Spain
- 13:15 Intravitreal dexamethasone implant use in coats disease
Rodrigo Molina Pallete, Spain
- 13:20 Q&A

Thursday, November 7, 2019 (CONT.)

13:30 - 15:30 **MANAGEMENT OF AMD**

13:30 - 14:50 **PART 1: IMAGING AND MANAGEMENT IN AMD**
Chairs: **Karina Berg**, Norway & **Paolo Lanzetta**, Italy

A. IMAGING: DIAGNOSIS AND FOLLOW UP

13:30 OCT angiography biomarkers in neovascular AMD
Luis Arias Barquet, Spain

13:35 Imaging in dry AMD
Alfredo Garcia-Layana, Spain

13:40 Non-exudative CNV: to treat or not?
Paolo Lanzetta, Italy

13:45 Hyper-reflective foci in AMD
Francesco Bandello, Italy

13:50 **Discussion**
Moderator: **Karina Berg**, Norway

When should we diagnose and treat? prior to clinical finding?
Current practice and role of imaging in AMD
Indications for fluorescein/indocyanin green

Thursday, November 7, 2019 (CONT.)

13:30 - 15:30 **MANAGEMENT OF AMD (CONT.)**

13:30 - 14:50 **PART 1: IMAGING AND MANAGEMENT IN AMD (CONT.)**
Chairs: **Karina Berg**, Norway & **Paolo Lanzetta**, Italy

B. TREATMENT

14:10 Management of polypoidal lesions (atlantic study)
Rufino Silva, Portugal

14:15 Key points of RIVAL study
Karina Berg, Norway

14:20 Treat and extend latest evidence with aflibercept (ALTAIR study)
Stela Vujosevic, Italy

14:25 Retreatment criteria for AMD (FLUID study)
Patricia Udaondo, Spain

14:30 **Discussion**
Moderator: **Paolo Lanzetta**, Italy

Does the regimen matter?

Management of bilateral wet AMD
Evidence or lack of it for ideal regimen
Evidence for TAE, addressing deteriorating lesions
Repeat loading dose vs. revert to previous step?
Guidance to discontinue treatment; the role of visual acuity

Thursday, November 7, 2019 (CONT.)

13:30 - 15:30 **MANAGEMENT OF AMD (CONT.)**

14:50 - 15:30 **PART 2: THE ROLE OF NEW MOLECULES?**

Chair: **Baruch Kuppermann**, USA

14:50 Brolucizumab
Javier Montero Hernandez, Spain

14:55 Abicipar phase III
Baruch Kuppermann, USA

15:00 Brimonidine tartrate in AMD
Albert Augustin, Germany

15:05 Update on complement inhibition results
Baruch Kuppermann, USA

15:10 **Discussion**
Moderator: **Albert Augustin**, Germany

The next strategic step: Improved delivery?
New chemical/biological entities vs. available drugs imported from other medical fields
New non-drug strategies?
When current therapy becomes ineffective, is there a next step?
Learning from lomalizumab failure; can we learn from the dementia studies failure?

15:30 *Coffee break*

Thursday, November 7, 2019 (CONT.)

16:00 - 18:00 **DIABETIC MACULAR EDEMA**
Chairs: **Patricia Udaondo**, Spain & **Stela Vujosevic**, Italy

IMAGING IN DME

16:00 Prognostic and predictive biomarkers in DME
Patricia Udaondo, Spain

16:05 Microvascular changes as predictor for DME progression
Maria Cristina Parravano, Italy

16:10 How can we define chronic DME?
Stela Vujosevic, Italy

16:15 Discussion
Moderator: **Stela Vujosevic**, Italy

Importance of biomarkers in clinical research and practice?
How can we use the available imaging biomarkers to guide the treatment?
The role of OCT-A in the diagnosis and management of DR/DME?
Pitfalls of currently available imaging biomarkers in DME

DME MANAGEMENT

16:30 Real world evidence with fluocinolone implant in DME
Francesco Bandello, Italy

16:35 Long term efficacy and safety of dexamethasone implant for DME
Alfredo Adan, Spain

16:40 Real life outcomes of anti-VEGF therapy in DME
Paolo Lanzetta, Italy

Thursday, November 7, 2019 (CONT.)

16:00 - 18:00

DIABETIC MACULAR EDEMA (CONT.)

Chairs: **Patricia Udaondo**, Spain & **Stela Vujosevic**, Italy

16:45

Take home messages of latest protocols of DRCR.net (T and V)

Patricia Udaondo, Spain

16:50

The EURETINA guidelines for DME

Karina Berg, Norway

16:55

Combined therapy in DME

Enrique Cervera, Spain

17:00

Discussion

Moderator: **Patricia Udaondo**, Spain

Combine therapy

Loading dose

Treating eyes with good visual acuity

Interpretation of protocol T results

Role for surgery

FORSEEN FUTURE IN DME

17:20

Phase II trials that succeeded and fail for DME: angiopoietin vs Tie2

Baruch Kuppermann, USA

17:25

Phase I first-in-human study of KSI-301: a novel anti-VEGF antibody biopolymer conjugate (ABC) with extended durability

J. Pablo Velazquez-Martin, USA

17:30

Drugs in pipeline for DME

Marc de Smet, Switzerland

17:35

Discussion

Moderator: **Marc de Smet**, Switzerland

Thursday, November 7, 2019 (CONT.)

18:00

SCIENCE MUSEUM & GET- TOGETHER RECEPTION

Friday, November 8, 2019

08:30 - 09:30

ADVANCED AMD

Chair: **Usha Chakravarthy**, UK

08:30

Review the pathogenesis of AMD and the pathways to CNV and GA

Jordi Mones, Spain

08:37

Discussion

08:45

Examine current therapeutics and consider the long-term outcomes and unmet need

Tunde Peto, UK

08:52

Discussion

09:00

Evaluate the current therapeutic pipeline critically assessing the appropriateness of targets

Usha Chakravarthy, UK

09:07

Discussion

09:15

Home OCT: improving AMD therapy with accessible data

Anat Lowenstein, USA

09:22

Discussion

09:30

Coffee break

Friday, November 8, 2019 (CONT.)

- 10:00 - 11:00 **ARTIFICIAL INTELLIGENCE**
Chairs: **Tunde Peto**, UK & **Leopold Schmetterer**, Singapore
- 10:00 Artificial Intelligence in retinal imaging
Javier Zarranz, Spain
- 10:10 Future in imaging. Functional Imaging
Tunde Peto, UK
- 10:20 Artificial Intelligence for glaucoma
Leopold Schmetterer, Singapore
- 10:30 AI in retinal disease - screening and ophthalmologist virtual assistant
Tamar Levi Vineberg, Israel
- 10:40 Discussion
-

- 11:00 - 12:00 **GENE THERAPY**
Chair: **Francine Behar-Cohen**, France
-

- 11:00 Human pluripotent stem cell therapy for the treatment of retinitis pigmentos
Karim Ben Mbarek, France
- 11:15 Viral gene therapy for wet AMD: where are we?
Marc de Smet, Switzerland
- 11:30 Non viral gene therapy: from concept to human trial
Francine Behar-Cohen, France
- 11:45 Non-viral gene therapy for neuroprotection
Karine Bigot, France

Friday, November 8, 2019 (CONT.)

12:00 - 13:30 **COMPANY SPONSORED LUNCH SESSION**

12:00 *Lunch served*

12:30 Sponsored session - see details on page 38

13:30 - 15:30 **DRUG DELIVERY**
Chairs: **Diane Tang Liu & Uday Kompella, USA**

13:30 Diabetic macular edema: pathophysiology and novel
therapeutic agents
Arup Das, USA

13:40 Targeted treatment of retinoblastoma with an oncolytic
adenovirus
Angel Montero Carcaboso, Spain

13:50 Nanoformulation as intraocular drug delivery system to target
the posterior segment
Martina Giannaccini, Italy

14:00 Microspheres as therapeutic systems to treat retinal diseases
Martia Del Rocio Herrero-Varnell, Spain

14:10 Biodegradable intraocular implants
Uday Kompella, USA

14:20 Sustained Release of small molecules and biologics using
photocrosslinked ocular drug delivery systems
Raghu Raj Thakur, UK

Friday, November 8, 2019 (CONT.)

13:30 - 15:30

DRUG DELIVERY (CONT.)

Chairs: **Diane Tang Liu** & **Uday Kompella**, USA

14:30

The vitreoretinal explant: a drug delivery model to promote the rational design of nanoparticles for retinal delivery

Karen Peynshaert, Belgium

14:40

Suprachoroidal drug delivery

Uday Kompella, USA

14:55

Discussion

15:30

Coffee break

CENTRAL SEROUS CHOROIDOPATHY

16:00 - 17:00

Chairs: **Francine Behar-Cohen**, France
& **Jose María Ruiz Moreno**, Spain

16:00

Imaging CSCR by SS-OCT and SS OCT-A

Jose María Ruiz Moreno, Spain

16:10

CSCR and blood flow

Mathilde Gallice, France

16:20

Current management of CSCR

Ibraheem El Ghrably, Abu Dhabi

16:30

CSCR and CNV

Jorge Ruiz Medrano, Spain

16:40

Anti-VEGF in neovascular CSCR

Francine Behar-Cohen, France

Friday, November 8, 2019 (CONT.)

CENTRAL SEROUS CHOROIDOPATHY (CONT.)

16:00 - 17:00

Chairs: **Francine Behar-Cohen**, France
& **Jose María Ruiz Moreno**, Spain

16:50

Change in choroid after half-fluency PDT
Ignacio Flores-Moreno, Spain

RETINAL VEIN OCCLUSION

17:00 - 17:45

Chairs: **Albert Augustin**, Germany
& **Manuel Saenz de Viteri**, Spain

17:00

Multimodal imaging: assessing non perfusion
Albert Augustin, Germany

17:05

The LEAVO trial
Usha Chakravarthy, UK

17:10

Long term efficacy of steroids in management of macular edema in vein occlusion
Ibraheem El Ghrably, Abu Dhabi

17:15

Latest evidence of anti VEGF in vein occlusion
Choi-Mun Chan, Singapore

17:20

Laser in vein occlusion: when and for what?
Manuel Saenz de Viteri, Spain

17:25

Discussion with clinical cases
Moderator: **Manuel Saenz de Viteri**, Spain

17:45

End of day's Sessions

Saturday, November 9, 2019

08:00 - 08:45 **INHIBITION OF DIABETIC RETINOPATHY**
Chair: **Arup Das**, USA

08:00 Targeting G-proteins to inhibit diabetic retinopathy
Renu Kowluru, USA

08:10 Kallikrein-kinin system in diabetic retinopathy - novel target
Edward Feener, USA

08:20 Targeting IL-6 signaling to intervene in the progression of
diabetic retinopathy
Susanne Mohr, USA

08:30 Combotherapy of diabetic retinopathy: emerging paradigm
Ashwath Jayagopal, Switzerland

08:45 - 09:30 **THERAPY OF RETINAL ANGIOGENESIS**
Chair: **Arup Das**, USA

08:45 Non-coding RNA based therapeutics
Subrata Chakarabarti, Canada

08:55 Control of retinal angiogenesis by modification of cell
membrane lipid composition and membrane fluidity
Julia Busik, USA

09:05 Inflammation in early diabetic retinopathy
John Penn, USA

09:15 Glial influence in the pathogenesis of diabetic retinopathy
Debasish Sinha, USA

Saturday, November 9, 2019 (CONT.)

09:30 *Coffee break*

10:00 - 11:20 **GENE THERAPY**
Chair: **Neena Haider & Margaret DeAngelis**, USA

10:00 Modifier gene therapy as a novel broad spectrum way to
treat retinal disease
Neena Haider, USA

10:10 Using genomics to characterize therapeutic targets for AMD
Margaret DeAngelis, USA

10:20 Precision medicine gene therapy for LCA16
Bikash Pattniak, USA

10:30 Gene therapy for X-linked retinitis pigmentosa with codon-
optimized AAV8-RPGR
Cristina Martinez, UK

10:40 Gene therapy for wet AMD using non-viral vectors
Manuel Saenz de Viteri, Spain

10:50 Novel gene therapy approaches for inherited retinal diseases
Jordi Mones, Spain

11:00 Q&A

Saturday, November 9, 2019 (CONT.)

11:20 - 12:00 **KEYNOTE LECTURE & FREE PAPERS**
Chair: **Ron Neumann**, Israel

KEYNOTE LECTURE:

11:20 Down to earth: harnessing artificial intelligence to improve retinal diagnosis and health
Dimitri Azar, USA

FREE PAPERS

11:35 Uveitis induced by brentuximab vedotin – a novel adverse response to antibody drug conjugate therapy
Gal Antman, Israel

11:40 Screening protocol and therapeutic options for the macular edema secondary to fingolimod treatment in patients with multiple sclerosis
David Salom, Spain

11:45 A prospective, non-randomized, multicenter study on the efficacy and safety of ILUVIEN® in diabetic macular edema patients considered insufficiently responsive to available therapies (REACT)
José María Ruiz Moreno, Spain

11:50 Zimura C5 complement inhibitor Phase 2b results
Kourous Rezaei, USA

12:00 *Lunch*

Saturday, November 9, 2019 (CONT.)

12:30 - 13:30 **THE EPHRAIM FRIEDMAN LECTURE & FREE PAPERS**
Chairs: **Usha Chakravarthy**, UK & **Javier Zarranz**, Spain

THE EPHRAIM FRIEDMAN LECTURE

12:30 Introduction:
Sara Krupsky & Ron Neumann, Israel

12:40 Neuroprotection for retinal diseases
Baruch Kuppermann, USA



FREE PAPERS

12:50 Ocular redox status and visual function after treatment with
an antioxidant mixture in patients with retinitis pigmentosa
Regina Rodrigo, Spain

12:55 Complex functional and morphological evaluation of the
retina after intravitreal administration of bone marrow-
derived cells population in retinitis pigmentosa
Marta P. Wiqcek, Poland

13:00 Tau protein in the retina
Umur A. Kayabasi, Turkey

13:05 Wide-based foveal pit- a normal variant or a predilection for
maculopathy?
I Hsin Ma, Taiwan

13:10 Efficacy of hyperbaric oxygen therapy on intraocular pressure
and nerve fiber layer with type 2 diabetic patients: a
prospective cohort study
Havva Kaldırım, Turkey

13:15 Ultra wide-field retinal imaging in cytomegalovirus retinitis
John Paul Liscombe, Spain

Saturday, November 9, 2019 (CONT.)

12:30 - 13:30 **FREE PAPERS (CONT.)**
Chairs: **Usha Chakravarthy**, UK & **Javier Zarranz**, Spain

13:20 Q&A

13:30 - 14:30 **DIABETIC RETINOPATHY**
Chairs: **Rufino Silva**, Portugal & **Francesco Boscia**, Italy

13:30 Comparison of FA and OCTA in DR
Javier Zarranz, Spain

13:37 Ultra-widefield swept source OCTA in DR
María Cristina Parravano, Italy

13:44 Diabetic retinopathy treated with anti-VEGF: results on clinical trials
Francesco Boscia, Italy

13:51 Update on DRCR.net studies in DR
Itay Chowers, Israel

13:58 Is it safe to space out injections when you are treating PDR with anti-VEGF alone?
Rufino Silva, Portugal

14:05 Surgery in DME: when and how?
Jose García Arumí, Spain

14:12 Discussion and clinical cases

Saturday, November 9, 2019 (CONT.)

- 14:30 - 15:30 **MYOPIA**
Chairs: **Jose García Arumí** & **Jose Maria Ruiz-Moreno**, Spain
- 14:30 Myopic maculopathy: new classification
Jose Maria Ruiz-Moreno, Spain
- 14:37 Factors influencing visual acuity in patients receiving anti VEGF for myopic CNV
Francesco Boscia, Italy
- 14:44 Update on myopic CNV management
Choi-Mun Chan, Singapore
- 14:51 The dome shaped macula and its potential treatments
Itay Chowers, Israel
- 14:58 When is surgery the option in myopic maculopathy?
Jose García Arumí, Spain
- 15:05 Discussion

15:30 *Coffee break*

Saturday, November 9, 2019 (CONT.)

16:00 - 17:30

CHALLENGING CASES

Chair: **Patricia Udaondo**, Spain

Middle age male with hypertension and visual disturbance
Enrique García-Soler, Spain

Unilateral vision loss
Aida Navarro Navarro, Spain

50 year old female with a retinal detachment
Alexandru Placinta, Spain

14 year old female with unilateral macular lesions and vision loss
Miguel Ortiz, Spain

81 year old female with bilateral floaters and blurred vision
Ana Lopez-Montero, Spain

Patient with low vision due to inherited retinal disease
Alvaro Rallo & Sonia Peñarrocha, Spain

17:30

End of day's Sessions

E-POSTERS

E-POSTERS

1. PHARMACOECONOMIC ANALYSIS OF INTRAVITREAL STEROIDS FOR DME AND HOSPITAL BUDGET IMPACT MODEL: CALCULATING THE COST SAVINGS FROM THE INTRODUCTION OF THE FLUOCINOLONE IMPLANT (ILUVIEN®) IN SPANISH HOSPITALS
Alfredo Adán, Francisco Cabrera, Jose Juan Escobar, Foix Aragones Tena, Javier Zarranz-Ventura, Spain
2. ANATOMICAL AND FUNCTIONAL RESPONSE AFTER THE SWITCH BACK FROM OZURDEX TO ANTI-VEGF IN PATIENTS WITH DIABETIC MACULAR EDEMA
Valentina Bilbao Malavé, Alfredo García Layana, Spain
3. ENDOSTATIN IS DECREASED IN THE RETINA OF DIABETIC DB/DB MICE
Aina Bonet Arribas, Marc Navarro, Andreia Valença, Luísa Mendes-Jorge, Jesús Ruberte, Spain & Portugal
4. BEVACIZUMAB AS FIRST-LINE THERAPY IN RETINOPATHY OF PREMATURITY
Uriel Rodrigo Butrón-Ruiz, Ester Torres-Martínez, Honorio Barranco-González, Laura Pérez-Lara, Javier Orts-Llácer, Jesús María Carpintero-Sánchez, Inmaculada Almor-Palacios, Spain
5. OCULAR ONCOLOGY-BASED INTERVENTIONAL CLINICAL TRIALS ANALYSIS
Nisarg Chhaya, Michael Migliori, Taygan Yilmaz, USA
6. MULTIMODAL IMAGING OF RETINA CAPILLARY HEMANGIOBLASTOMA EMERGING FROM THE OPTIC DISC: A CASE REPORT
Ana Maria Cunha, Ana Filipa Moleiro, Teresa Bragança Dinah, Elisete Brandão, Fernando Falcão-Reis, Portugal
7. SUPPRESSION OF CHOROIDAL NEOVASCULARIZATION (CNV) BY CO-SUPPRESSION OF PDGF AND VEGF SIGNALING – A CLOSER LOOK ON MÜLLER GLIA
Nundehui Diaz Lezama, Anne Wolf, Thomas Langmann, Antje Grosche, Germany
8. RETINAL ARTERIAL MACROANEURYSMS
Sara Fathi Nieto, Paula Martínez López-Corell, Enrique García Soler, Uriel Rodrigo Butrón Ruiz, Patricia Udaondo Mirete, Spain

E-POSTERS (CONT.)

9. CURCUMIN-BASED TREATMENT FOR MACULAR EDEMA FROM UNCOMMON ETIOLOGIES: EFFICACY AND SAFETY ASSESSMENT
Mariantonia Ferrara, Davide Allegrini, Tania Sorrentino, Giancarlo Sborgia, Francesco Parmeggiani, Alfredo Borgia, Mario Romano, Italy
10. CANDIDA ALBICANS BILATERAL FUNGAL ENDOPHTHALMITIS TREATED WITH ORAL AND INTRAVITREAL VORICONAZOLE
Amanda García Tirado, Enebrales Recio Gamó, Spain
11. MANAGEMENT OF CYTOMEGALOVIRUS RETINITIS (CMV) IN A PATIENT WITH ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) AND SUBSEQUENT DEVELOPMENT OF IMMUNE RECOVERY UVEITIS
Amanda García Tirado, Ignacio Terrance, Enebrales Recio Gamó, Spain
12. INTERVENTIONAL RANDOMIZED STUDY OF NUTRITIONAL SUPPLEMENTATION IN PATIENTS WITH UNILATERAL WET AMD
Alfredo García-Layana, Sergio Recalde-Maestre, Patricia Fernández-Robredo, Maximino J Abraldes, João Cruz Nascimento, Emiliano Hernández-Galilea, Begoña Olmedilla-Alonso, Jose Juan Escobar-Barranco, Miguel Angel Zapata-Victori, Rufino Silva, Mariana Caballero-Arredondo, M.Carmen Lopez-Sabater, Pilar Calvo, Spain & Portugal
13. EXPLORATION OF THE NEW THERAPEUTIC APPROACHES IN THE TREATMENT OF DIABETIC RETINOPATHY THROUGH PTEROSTILBENE
Carmen M Descó-Esteban, **Guillermo Rodríguez-Iranzo**, Jorge Mataix-Boronat, Ivan Millan-Yañez, Salvador Perez-Garrido, Maria Isabel Lopez-Cuevas, Ines Pulido, Salvador Mena, Angel Ortega, Miguel A Asensi, Spain
14. RESOLUTION OF RETINAL VASCULAR LEAK WITH ORAL JAK KINASE INHIBITOR TOFACITINIB
Doaa Kerwat, Nada Hassan, Avinash Gurbaxani
UK & United Arab Emirates
15. TOPOGRAPHIC CHANGES OF THE CHOROIDAL THICKNESS IN AGE-RELATED MACULAR DEGENERATION DURING DEVELOPMENT OF CHOROIDAL NEOVASCULARIZATION
Seong Woo Lee, Jae Yong Park, Je Hyung Hwang, Jae Suk Kim, Republic of Korea

E-POSTERS (CONT.)

16. CHANGES IN INNER RETINAL LAYER THICKNESS IN PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION DURING TREATMENT WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR
Seong Woo Lee, Jae Yong Park, Je Hyung Hwang, Jae Suk Kim, Republic of Korea
17. DISCONTINUATION AND NONPUBLICATION OF INTERVENTIONAL CLINICAL TRIALS AMONG ANTI-VEGF TRIALS
Dean Loporchio, Salvatore Loporchio, Michael Migliori, Taygan Yilmaz, USA
18. DIFFERENTIAL DIAGNOSIS IN OPTIC NEUROPATHY IN A DIABETIC YOUNG PATIENT
Lucía Ramos-González, **Paula Martínez-López Corell**, Rodrigo Molina-Pallete, Emma Marín-Paya, Javier Orts-Llácer, Jesús María Carpintero-Sánchez, Patricia Udaondo, Spain
19. COMPARISON OF POSTOPERATIVE OUTCOME OF INTERNAL LIMITING MEMBRANE PEELING AND INTERNAL LIMITING MEMBRANE FLAP IN MACULAR HOLE SURGERY
Sangwoo Moon, Seungkwon Choi, Republic of Korea
20. ANALYSIS OF EXPRESSION LEVEL CHANGES IN COLLAGEN GENES CAUSED BY ATROPINE AND 7-METHYLXANTHINE FOR EVALUATING THEIR EFFECTS ON COLLAGENS IN MOUSE RETINA.
Hiroyuki Nawase, Tatsukata Kawagoe, Akira Meguro, Nobuhisa Mizuki, Japan
21. THE INHIBITORY EFFECT OF D2 DOPAMINERGIC AGONISTS ON STIMULATED ANGIOGENESIS AND VEGF AND VEGF-R GENES EXPRESSION IN ZEBRAFISH MODELS
Maciej Krzysztof Oseka, Anna Swiech-Zubilewicz, Katarzyna Danieluk, Joanna Dolar-Szczasny, Jerzy Mackiewicz, Poland
22. QUANTITATIVE ANALYSIS OF RETINAL MICROVASCULAR CHANGES IN MACULAR TELANCGIECTASIA TYPE 2 USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY
Young Gun Park, Republic of Korea
23. MULTIMODAL IMAGING IN UNILATERAL PURTCHER'S DISEASE
Martín Puzo Bayod, Carmen A. Porcar Plana, Clara Martínez Rubio, Spain

E-POSTERS (CONT.)

24. OZURDEX VS ILUVIEN: THICKNESS AT FIRST SIGHT. A CASE SERIES.
Maria del Mar Schilt-Catafal, Patricia Bayo-Calduch,
Jose Miguel Vilaplana-Mora, Delia Hernández-Pérez,
Laura Manfreda-Domínguez, Francisca García-Ibor,
Noemí Ruiz-Del-Río, Vicente T. Pérez-Torregrosa, Raúl Martínez-Belda,
Antonio M. Duch-Samper, Spain

25. MACULAR STAR AND CAPILLARY MACROANAEURISM IN MACTEL TYPE-1 STUDY VALUE WITH MULTIMODAL IMAGE.
Hugo Ernesto Tapia Quijada, Sandra Gomez Perera,
Miguel Serrano Garcia, Cristina Mantolan Sarmiento, Spain

26. RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION AND SEROUS RETINAL DETACHMENT SECONDARY TO BILATERAL CHOROIDAL OSTEOMA. THREE YEAR FOLLOW-UP
Sandra Gomez Perera, **Hugo Ernesto Tapia Quijada**,
Cristina Mantolan Sarmiento, Miguel Serrano Garcia, Spain

27. RECURRENT MACULAR EDEMA RELATED TO PERFLUOROCARBON LIQUID(PFCL) BUBBLE IN ANTERIOR CHAMBER.
Hugo Ernesto Tapia Quijada, Miguel Serrano Garcia,
Cristina Mantolan Sarmiento, Luis Cordovez Dorta, Spain

28. TOBRAMYCIN RETINAL TOXICITY IS IMPORTANT TO KEEP IN MIND
Hugo Ernesto Tapia Quijada, Jose Valls Martinez, Spain

29. PARACENTRAL ACUTE MIDDLE MACULOPATY (PAMM) IN RETINIAN VASCULITIS BY PRESUMED TUBERCULOSIS (TB)
Hugo Ernesto Tapia Quijada, Sandra Gomez Perera,
Miguel Serrano Garcia, Cristina Mantolan Sarmiento, Spain

COMPANY SPONSORED SESSION



Friday, November 8, 2019

12:30 - 13:30	PRESENT & FUTURE IN THE MANAGEMENT OF nAMD Chair: Patricia Udaondo , Spain
12:30	Welcome and introduction Patricia Udaondo , Spain
12:35	Challenges and opportunities in nAMD management Anat Loewenstein , Israel
12:50	Updates from advanced clinical programs: new potential for disease control Jordi Mones , Spain
13:05	Importance of fluid control in nAMD: an AI analysis of real world data Usha Chakravarthy , UK
13:20	Panel discussion and close Moderator: Patricia Udaondo , Spain

ACKNOWLEDGEMENTS

The Organizers wish to acknowledge the following companies, whose generous support has made this Symposium possible.

COMPANY SPONSORED SESSION



EDUCATIONAL GRANT



Karger ad, process, (full page, no footer)